Page last updated: 2024-08-21

indazoles and pha 408

indazoles has been researched along with pha 408 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's5 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chiang, PC; Kishore, NN; Thompson, DC1
Hwang, JW; Kishore, N; Rahman, I; Rajendrasozhan, S; Yao, H1
Hall, T; Kishore, N; Kurumbail, RG; Mathialagan, S; Mbalaviele, G; Poda, GI; Reitz, BA; Selness, SR; Weinberg, RA1
Bonar, SL; Brustkern, SJ; Chen, NX; Christine, L; Heier, RF; Hu, Y; Huang, HC; Kishore, NN; Kurumbail, RG; Lennon, PJ; Li, X; Mathialagan, S; Poda, GI; Reding, MT; Selness, SR; Sommers, CD; Venkatraman, N; Wolfson, SG; Xie, J1
Chuang, TH; Hsu, LC; Lai, CY; Lin, KI; Su, YW1

Reviews

1 review(s) available for indazoles and pha 408

ArticleYear
Natural Modulators of Endosomal Toll-Like Receptor-Mediated Psoriatic Skin Inflammation.
    Journal of immunology research, 2017, Volume: 2017

    Topics: Aminoquinolines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Cytokines; Dermatitis; Endosomes; Humans; Imiquimod; Indazoles; Isonicotinic Acids; Mice; Psoriasis; Resveratrol; Signal Transduction; Skin; Stilbenes; Toll-Like Receptor 7; Toll-Like Receptor 8; Toll-Like Receptor 9; Toll-Like Receptors

2017

Other Studies

4 other study(ies) available for indazoles and pha 408

ArticleYear
Combined use of pharmacokinetic modeling and a steady-state delivery approach allows early assessment of IkappaB kinase-2 (IKK-2) target safety and efficacy.
    Journal of pharmaceutical sciences, 2010, Volume: 99, Issue:3

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Evaluation, Preclinical; Female; I-kappa B Kinase; Indazoles; Isonicotinic Acids; Male; Models, Biological; Rats; Rats, Inbred Lew; Rats, Wistar; Tumor Necrosis Factor-alpha

2010
Anti-inflammatory effect of a selective IkappaB kinase-beta inhibitor in rat lung in response to LPS and cigarette smoke.
    Pulmonary pharmacology & therapeutics, 2010, Volume: 23, Issue:3

    Topics: Animals; Bronchoalveolar Lavage Fluid; Dose-Response Relationship, Drug; I-kappa B Kinase; Indazoles; Inflammation Mediators; Isonicotinic Acids; Lipopolysaccharides; Lung; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; Smoking

2010
Expression, purification and functional characterization of IkappaB kinase-2 (IKK-2) mutants.
    Protein expression and purification, 2010, Volume: 72, Issue:2

    Topics: Animals; Cells, Cultured; Computer Simulation; Drug Discovery; Humans; I-kappa B Kinase; Indazoles; Isonicotinic Acids; Kinetics; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Phosphorylation; Protein Binding; Recombinant Proteins; Spodoptera; Structural Homology, Protein

2010
Aminopyridinecarboxamide-based inhaled IKK-2 inhibitors for asthma and COPD: Structure-activity relationship.
    Bioorganic & medicinal chemistry, 2011, Feb-01, Volume: 19, Issue:3

    Topics: Administration, Inhalation; Aminopyridines; Asthma; Binding, Competitive; Drug Design; HEK293 Cells; Humans; I-kappa B Kinase; Indazoles; Isonicotinic Acids; Microsomes, Liver; Models, Molecular; Molecular Structure; Molecular Targeted Therapy; Niacinamide; Phenethylamines; Potassium Channel Blockers; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrazoles; Structure-Activity Relationship; Sulfonamides

2011